Current evidence does not support cannabinoids for OCD, but psilocybin shows a stronger signal for treatment-resistant cases
A scoping review found very limited evidence for cannabinoids in OCD treatment, consisting mainly of surveys and case reports with no well-controlled trials, while psilocybin showed a stronger preliminary signal for treatment-resistant OCD.
Quick Facts
What This Study Found
The evidence for cannabinoids in OCD consists of cross-sectional surveys, case reports, and very few controlled trials, and appears to indicate a lack of efficacy for both synthetic and natural cannabinoids. In contrast, psilocybin shows a stronger signal for treatment-resistant OCD. 40-60% of OCD patients remain unresponsive to standard pharmacotherapy.
Key Numbers
40-60% of OCD patients are treatment-resistant. Cannabinoid evidence: cross-sectional surveys and case reports, no rigorous RCTs. No support for synthetic or natural cannabinoids in OCD. Psilocybin shows stronger preliminary signal.
How They Did This
Comprehensive scoping review of OCD literature including published and grey literature, examining evidence for cannabinoids, psilocybin, LSD, DMT, and MDMA in OCD treatment.
Why This Research Matters
With 40-60% of OCD patients treatment-resistant, interest in novel agents is high. This review provides a reality check: despite enthusiasm, cannabinoid evidence for OCD is essentially absent, redirecting attention toward psychedelics where the signal appears stronger.
The Bigger Picture
This review highlights an important distinction: cannabis users with OCD may self-report symptom relief in surveys, but controlled research does not support cannabinoids as an effective OCD treatment. The disconnect between self-reported benefit and clinical evidence is a recurring theme in cannabinoid research.
What This Study Doesn't Tell Us
Scoping review, not a systematic review with meta-analysis. The absence of evidence for cannabinoids does not prove absence of effect. Very few studies exist for any of the agents reviewed. Comparison across substance classes is indirect.
Questions This Raises
- ?Why do some OCD patients report subjective improvement with cannabis despite negative controlled evidence?
- ?Could specific cannabinoid formulations or doses be effective where general cannabis is not?
- ?Should research resources focus on psilocybin over cannabinoids for OCD?
Trust & Context
- Key Stat:
- No controlled evidence for cannabinoids in OCD; psilocybin more promising
- Evidence Grade:
- Moderate: comprehensive scoping review covering multiple substance classes, limited by the sparse evidence base for all agents reviewed.
- Study Age:
- Published 2026.
- Original Title:
- New treatments for OCD? Evidence for cannabinoids and psychedelics.
- Published In:
- Journal of psychiatric research, 193, 172-178 (2026)
- Authors:
- Van Ameringen, Michael(3), Patel, Vidhi, Patterson, Beth(2), Hopkinson, Paige, Rahat, Maryam
- Database ID:
- RTHC-08680
Evidence Hierarchy
Maps out the available research on a broad question.
What do these levels mean? →Frequently Asked Questions
Can cannabis help with OCD?
Current evidence does not support this. A scoping review found that cannabinoid evidence for OCD is limited to surveys and case reports, with no well-controlled trials showing efficacy.
What alternative treatments exist for treatment-resistant OCD?
This review found that psilocybin shows a stronger preliminary signal than cannabinoids for treatment-resistant OCD, though rigorous controlled trials are still needed for all novel agents.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-08680APA
Van Ameringen, Michael; Patel, Vidhi; Patterson, Beth; Hopkinson, Paige; Rahat, Maryam. (2026). New treatments for OCD? Evidence for cannabinoids and psychedelics.. Journal of psychiatric research, 193, 172-178. https://doi.org/10.1016/j.jpsychires.2025.11.021
MLA
Van Ameringen, Michael, et al. "New treatments for OCD? Evidence for cannabinoids and psychedelics.." Journal of psychiatric research, 2026. https://doi.org/10.1016/j.jpsychires.2025.11.021
RethinkTHC
RethinkTHC Research Database. "New treatments for OCD? Evidence for cannabinoids and psyche..." RTHC-08680. Retrieved from https://rethinkthc.com/research/van-2026-new-treatments-for-ocd
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.